Loading stock data…
Olema Pharmaceuticals (OLMA)
$12.20+0.81 (+7.11%)
After Hours$12.00-0.20 (-1.64%)· Last close Jun 29
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Olema Pharmaceuticals, Inc. in the Healthcare sector is trading at $12.20 with a market capitalization of $830M. Wall Street consensus targets $40.70 (10 analysts), implying a +233.6% move over the next 12 months. The stock is currently 66% below its 52-week high of $36.26, remaining 28.9% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +233.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$57.99M↓ | -$50.08M↓ | -$45.88M↑ | -$47.86M↓ | -$34.87M |
| Net Income | -$53.09M↓ | -$46.06M↓ | -$42.22M↑ | -$43.78M↓ | -$30.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$830.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.53%
Volume
Today's trading volume
1.41M
Recent News
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the small-cap stocks with potential to rise 1000 percent. The company gave investors a new pipeline marker on May 21, when it reported initial Phase 1 clinical data for OP-3136, its KAT6 inhibitor, at the 2026 ASCO Annual Meeting. Olema said OP-3136 monotherapy was well-tolerated, with no dose-limiting […]
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap
Olema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tumor shrinkage and a clean safety profile in patients with difficult-to-treat cancers. More detailed results are scheduled to be presented at the 2026 ASCO Annual Meeting. For investors tracking oncology pipelines, this update puts more attention on Olema Pharmaceuticals, which is developing...
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study
Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
Investor Stanley Druckenmiller’s Duquesne Family Office exited a 385,000 share position in Alphabet in the first quarter.
Assessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The Board
Olema Pharmaceuticals (OLMA) has drawn fresh attention after appointing Prakash Raman, Ph.D., to its Board of Directors. This move puts an experienced oncology and immunology dealmaker closer to the company’s pipeline decisions. See our latest analysis for Olema Pharmaceuticals. Investors have seen sharp swings in Olema’s share price, with a 5.0% 7 day share price return contrasting with a 40.3% 90 day share price decline, while the 1 year total shareholder return of roughly 2.2x points to...